Loblaw Companies Limited Q2 2026 Earnings Recap

Loblaw's shares declined modestly by 0.3% following a largely in-line quarter with steady revenue growth and stable margins, but without clear upside catalysts to move the stock higher.

Key Takeaways

• Q2 revenue rose 4.1% to $15 billion, driven by new store openings and positive same-store sales.
• Adjusted EBITDA increased 5.1% to $1.9 billion, with a slight 10-basis-point improvement in margin.
• Adjusted EPS grew 11.9% to $0.66, reflecting operational consistency but no surprising acceleration.
• Food retail same-store sales increased 1.6%, including a 20-basis-point drag from recent store rollouts; hard discount banners led with roughly 4% comp growth.
• Drug retail same-store sales growth of 4.6%, driven by a 7.5% increase in pharmacy and healthcare services, though early indications of generic GLP-1 impact remain uncertain.